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ABSTRACT
Objective: To evaluate the relationship of phenytoin-induced
gingival enlargement and inflammation to find out if there is
any significant correlation between hyperplastic index and
periodontal parameters, the number of fibroblasts and
phagocytic cells.
Background: The introduction of phenytoin as an anti-epileptic
drug in 1938 marked the beginning of a new era in the treatment
of grandmal epileptic patients decreasing significantly not only
the epileptic attacks but also improving the quality of life.
However, there is concern in dentistry regarding  gingival
overgrowth as a side-effect. A histological study of this tissue
can shed some light on the changes taking place.
Materials and methods: Twenty-four epileptic patients on
phenytoin therapy were divided into two groups as follows:
• Group I or test group of individuals who had been suffering
from gingival enlargement,
• Group II or control patients taking phenytoin without any
gingival enlargement.
Plaque, gingival and hyperplastic indices of anterior teeth
were determined in all the subjects. Biopsy specimens  of all
patients were taken and subjected to histopathological
examination to determine the number of fibroblasts,
macrophages, lymphocytes, and the level of inflammation,
capillary proliferation and collagenation.
Results: There is a significant increase in number of fibroblasts,
macrophages, lymphocytes,collagenation and capillary
proliferation  in the enlarged gingiva of test group as compared
to the control group.
Conclusion: The degree of inflammation increases with the
degree of enlargement. There is an increase in angiogenesis
and the number of phagocytic cells thus indicating that
phenytoin exerts growth promoting effects on the connective
tissues.
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INTRODUCTION
Epilepsy is a collective term for a group of chronic
convulsive disorders having in common, sudden transient
episodes of loss or disturbance of consciousness, usually
but not always with a characteristic body movement
(convulsions) and sometimes with autonomic hyperactivity.
John Hughlings Jackson postulated about a century ago that
epileptic seizures were caused by occasional, sudden,
excessive, rapid, local disturbances of gray matter. The
normal brain contains billions of neurons which ‘fire’
asynchronously. Inhibitory feedback loops in the normal
brain regulate the frequency of firing of individual neurons
and prevent synchronization. When such an inhibitory
feedback is defective, a large number of cells in a given
area of the brain fire at the same time and produce a self-
regenerative electrical impulse. Such an arc constitutes an
epileptic focus.
Such foci may be cortical or subcortical. They may
discharge intermittently, only to be shown up on the gross
surface EEG but not cause symptoms because their spread
is blocked by the normal inhibitory mechanisms in the
surrounding brain tissue. Factors which themselves cannot
initiate seizures may trigger off the abnormal focus as they
permit the spread of activity to the normal brain. Such factors
include alkalosis, hypoglycemia, overhydration,
hypocalcemia, overeating, strong emotional states, such as
fright or embarrassment, various stages of sleep, intake of
alcohol and rapid blinking of eyes or other rhythmic phonic
stimulation. The clinical type of seizure is independent of
the brain pathology but is determined by the site of the
abnormal focus and by the path taken by the seizure
discharge. The response to treatment correlates best with
the site of the epileptogenic focus.1
Many types of anticonvulsive drugs have been extensively
used in the treatment of grand mal and other types of
epilepsy. These drugs play a significant role in the control
of convulsions and also in their prevention of recurrence,
thus relieving the agony of disease. Out of several drugs
used, the most commonly used drugs in the treatment of
epilepsy are phenytoin and phenobarbitone, a barbiturate.
These may be considered as ‘life saving group of drugs’.
Apart from producing beneficial effects, these drugs,
particularly phenytoin, show certain side effects like gingival
enlargement on oral administration. This drug seems to
possess a selective stimulating effect on the fibroblasts of
the gingival connective tissue causing excessive formation
of fibrous tissue.
10.5005/jp-journals-10026-1026
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It has been pointed out in the literature that compounds
containing urea radicle have a tendency to produce
fibroblastic stimulating effect and cause excessive
proliferation of fibrous tissue. Hence, in the light of the
above fact that diphenylhydantoin (DPH) contains a urea
radicle the cause of gingival enlargement is well-established.
The severity of phenytoin (PHT) induced gingival
overgrowth and its correlation with dental plaque calculus
formation and gingival inflammation has been well
documented.2-5 Inflammation seems to be an important
cofactor in PHT-induced gingival overgrowth in both
animals and man.
These observations imply some supportive or synergistic
role for one or more of the inflammatory cells with the
mitogenic effects of PHT on connective tissue fibroblasts.6
Since, both macrophages and lymphocytes are known to
have critical roles in the repair of inflamed connective tissue,
these cells were found to be strong candidates for
involvement in the PHT-induced growth process.7
PHENYTOIN PHARMACOLOGY
The discovery of antiepileptic drugs is a breakthrough in
the era of pharmacotherapeutics. Some of these drugs are
highly indispensable to the suffering of mankind. One of
them being diphenylhydantoin introduced by Merritt and
Putnam in 1938 with great success in controlling epileptic
seizure particularly the grand mal type. It is the primary
drug in the treatment of epileptic seizures with the exception
of petit mal. It is otherwise called as dilantin sodium. DPH
is obtained by the combination of urea and glycolic acid
forming glycolylurea, otherwise called hydantoin. If
diphenyl radicals are substituted for hydrogen, then it is
called DPH.
MODE OF ACTION
It exerts a selective antiepileptic action without causing
drowsiness. The onset of action is slow even on intravenous
injection but the action persists for a considerable time after
cessation of therapy. This is thought to be due to the light
binding of the drug to the nervous tissue. The exact mode of
action of this drug is not known, probably, it inhibits the spread
of seizure discharges in the brain and shortens the duration
after discharge. In patient in whom it is effective, the
generalized abnormality in EEG disappears but the abnormal
focal electrical activity persists, unlike phenobarbitone, the
drug fails to produce a significant alteration in the
electroshock seizure threshold in normal animals. The
threshold may, however, be elevated to a moderate extent
after prolonged therapy. The drug has no protective effect
against leptazol-induced convulsions in animals.
The drug is known to decrease the neuronal sodium
concentration leading to a reduction in the post-tetanic
potentiation (PTP) and to increase the neuronal potassium
concentration. The work of Woodbury et al indicates that
the stabilizing effect of PHT is closely related to its ability
to decrease the intraneuronal sodium concentration. The
drug has a stabilizing effect on all neuronal membranes
including the peripheral nerve membrane as well as on all
nonexcitable and excitable membranes.
Phenytoin also augments brain level gamma amino
butyric acid (GABA) as well as 5-HT and homovanillic acid.
The restored balance between the excitatory glutamate and
inhibitory GABA pathways by PHT might be contributory
to its antiepileptic action. PHT is slowly and variably
absorbed from the gut and its peak in the plasma occurs
3 to 12 hours after ingestion. It is metabolized mainly by
parahydroxylation of one of its phenyl rings in the liver. It
is excreted in the urine and in saliva.
ADVERSE REACTIONS
Such reactions are generally mild and only rarely do they
enforce a cessation of therapy. Plasma levels of over
20 mg/ml are generally associated with adverse reactions.
Introducing of this drug may lead to urticarial,
scarlatiniform and measles like skin rashes may occur more
frequently in children and in young adults. Hypertrichosis
and hirsutism related to increased adrenocortical activity
sometimes occurs in females. PHT may lead to
vestibulocerebellar syndrome characterized by vertigo,
ataxia, nystagmus and dysarthria, others effects like
drowsiness, fatigue, headache and confusion are
occasionally observed.
Ocular pain with blurring of vision, delusions,
hallucinations and other psychotic episodes are sometimes
encountered. Peripheral neuropathy has been reported in
old people receiving large doses for many years. Gastric
irritation, resulting in nausea and vomiting caused by the
alkalinity of the drug, can be prevented by taking the total
daily dose in individual portions, after meals, with plenty
of fluids. Megaloblastic anemia responding to folic acid
and rarely, blood dyscrasias including aplastic anemia,
pancytopenia, leukopenia, agranulocytosis may appear. PHT
has marked enzyme inducing properties and can stimulate
the metabolism of many drugs, such as contraceptives,
steroids, coumarin anticoagulants, glucocorticoids and
vitamin D, thereby reducing their therapeutic efficacy.
Dangerous hyperglycemia has been reported in diabetics
receiving PHT. This is probably due to inhibition of insulin
secretion by PHT.
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GINGIVAL ENLARGEMENT
Its reported incidence varies from 3 to 84.5% and it occurs
more frequently in younger patients,2 Babcock JR (1965),
Kimbal OP (1939) was the first person to report gingival
hyperplasia due to DPH.8 The primary basic lesion starts as
a painless, bead like enlargement on the facial and lingual
gingival margins and interdental papillae. When
uncomplicated by inflammation, the lesion is mulberry
shaped, firm, pale pink and resilient, with a minutely
lobulated surface and no tendency to bleed. The enlargement
characteristically appears to project from beneath the
gingival margin, from which it is separated by a linear
groove.9,10 The hyperplasia is usually generalized throughout
the mouth but it is more severe in the maxillary and
mandibular anterior regions.
HISTOPATHOLOGY
Most of the histopathological investigations that were carried
out on DPH induced gingival hyperplasia are by using
conventional staining method (H&E) and the observations
are reported by light microscopy. The enlargement entails
pronounced hyperplasia of the connective tissue and
epithelium. There is acanthosis of epithelium and elongated
rete pegs extending deep into the connective tissue, which
exhibit densely arranged collagen bundles with an increase
in the number of fibroblasts and new blood vessels.9,10
MATERIALS AND METHODS
Twenty-four patients were examined to access the periodontal
status of their upper and lower anterior teeth. All individuals
gave informed consent to participate in the study:
The selection criteria for the patients were as follows:
• The patients taking phenytoin drug.
• Patients who possessed their six upper and six lower
anterior teeth were eligible for study.
• None of the patients examined were on antihypertensive
therapy or any other medication known to produce
gingival enlargement.
STUDY DESIGN
Twenty-four patients, who satisfied above criteria, were
selected for study. All examinations were conducted with
subject sitting in the dental chair under standardized
illumination with a dental mirror and a standardized
graduated periodontal probe.
The epileptic patients were divided into a test group of
12 individuals on PHT who had been suffering from gingival
hyperplasia and 12 patients taking PHT without enlargement
taken as negative control.
Periodontal health of all the patients was assessed by
the following parameters.
Parameters of Periodontal Health
Plaque Index
Plaque levels of the labial, lingual and interproximal surfaces
of the 12 anterior teeth were scored according to plaque
index by Silness and Loe (1964).11
Grades Criteria
0 No plaque in the gingival area.
1 A film of plaque adhering to the free gingival margin and
adjacent area of the tooth. The plaque may be recognized
only by running a probe across the tooth surface.
2 Moderate accumulation of soft deposits within the gingival
pocket and on the gingival margin and or adjacent tooth
surface that can be seen by naked eye.
3 Abundance of soft matter within the gingival pocket and
on the gingival margin and adjacent tooth surface.
The plaque index for each subject was determined by
adding the individual scores and dividing this by the number
of surfaces scored. The gingival conditions were assessed
using the gingival index (GI) as given by Loe and Silness
(1963).11
Gingival Index
Grades Criteria
 0 Normal gingiva
 1 Mild inflammation, slight change in color, slight
edema, no bleeding on palpation
 2 Moderate inflammation, redness, edema and glazing,
bleeding on probing
 3 Severe inflammation, marked redness and edema,
ulceration, tendency to spontaneous bleeding.
The tissues surrounding each tooth are divided into four
gingival scoring units.
a. Distofacial papilla
b. Facial margin
c. Mesiofacial margin
d. Entire lingual margin
A blunt instrument, such as a periodontal pocket probe,
is used to assess the bleeding potentials of the tissues.
Totaling the scores around each tooth yields, the gingival
index score for the area. If the scores around each tooth are
totaled and divided by four, the gingival index scores for
the tooth is obtained. Totaling all of the scores per tooth
and divided by the number of teeth examined provides the
GI score per person. Criteria for assessing gingival thickness
in a labiolingual direction for a gingival unit. The numerical
score of the GI are associated with varying degrees of clinical
gingivitis as follows:
Gingival score Degree of gingivitis
0.1-1.0 Mild
1.1-2.0 Moderate
2.1- 3.0 Severe
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Assessment of Gingival Hyperplasia
Gingival hyperplasia was assessed for the 12 anterior teeth;
using a semiquantitative hyperplastic index (HI). It is
comprised of two components that measure independently
the vertical and horizontal extension of gingival enlargement.
The hyperplasia was measured in the patient’s mouth using
a calibrated periodontal probe. The upper and lower arches
are divided into five gingival units (anteriorly) both buccally
and lingually, according to the method developed by
Seymour et al 1985.12 Each unit was from the buccal or
lingual midpoint of a tooth, the midpoint of the adjacent
tooth, extending from 13 to 23 in the upper arch, and from
33 to 43 in the lower arch.
The vertical component of the HI measured, the degree
of gingival enlargement in an apicocoronal direction
(vertical) for a gingival unit and was graded by means of a
4-point interval scale (Table 1). This vertical component of
the HI has been used as the sole index for assessing gingival
enlargement by Hassell TM et al,13 Conard et al (1947).14
The horizontal component of the HI developed by Seymous
et al (1985) measured the degree of gingival thickening on
both the labial and lingual aspect in a labiolingual direction
(horizontal) for a gingival unit (Table 2).
The vertical and horizontal scores were added, thus
giving a hyperplasia score for each gingival unit. The
maximum score obtainable using this method is five. As 20
gingival units were examined, the degree of hyperplasia
around upper and lower anterior teeth was expressed as a
percentage (Seymour et al 1985).12
The horizontal component of the hyperplastic index,
developed by Seymour et al 198512 measured the degree of
gingival thickening on both the labial and lingual direction
(horizontal).
For a gingival unit:
Grades Criteria
0 Normal width of free gingival margin
1 Thickening from the normal up to 2 mm
2 Thickening from the normal and > 2 mm
Procedure for quantification of fibroblastic and
phogocytic cells in the PHT-induced connective tissues.
Quantification of fibroblasts and phagocytic cells can be
done by making smears from the PHT-induced gingival
enlargement biopsies.
Before biopsy was taken complete oral prophylaxis was
done. After reviewing the case for a period of 15 days, biopsy
was taken.
Biopsy
The biopsy specimens were obtained from all the 24 patients
belonging to the two groups under local anesthesia
(lignocaine hydrochloride 2% with adrenaline). In the PHT-
induced gingival enlargement cases, the hyperplastic tissue
is taken as the biopsy. In the control group, the lingual
mucosa adjacent to lower left second premolar and first
molar was taken as biopsy tissue. The technique employed
to obtain the specimen was incisional biopsy technique. The
biopsy material was immediately fixed in 10% potassium
buffered formalin following adequate fixation, they were
processed by conventional methods and paraffin blocks were
made and sectioned on a Reichert Histostat rotary
microtome, sections made and stained with hematoxylin and
eosin solutions.
The slides were examined under a compound microscope
with a magnification of ×100. In the histopathological view
of the slides, the number of fibroblasts, macrophages,
lymphocytes, the amount of papillary proliferation, the
amount of collagenation, whether their is acanthosis or not
and degree of inflammation was seen. As it is impossible to
count the number of different cells in the sections, we have
graded them into 0, +, ++ and +++ depending on the number
of cells present in the sections.
Table 1: Vertical hyperplastic index or apicocoronal component
Grade Criteria
0 No gingival hyperplasia
1 Mild hyperplasia (blunting of gingival margin)
2 Moderate hyperplasia (less than 1/2 of crown length)
3 Marked hyperplasia (greater than 1/2 of crown length)
Division of upper and lower anterior teeth into gingival units
(MGL = mucogingival line)
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• 0: Zero or negligible number of cells in some sections.
• +: Cells present in all the sections but in medium density
in few sections.
• ++: Cells present in all the section but in high density in
limited section.
• +++: Cells present in all the sections of the slide in high
density.
RESULTS
A total of 24 patients were taken for the study. They were
divided into two groups.
Group I: Test group—this consists of 12 patients taking
PHT with gingival hyperplasia (Fig. 1). Group II: Control
group—this consists of 12 patients taking PHT and without
gingival hyperplasia (Fig. 2).
Results of group I: It consists of 12 epileptic patients under
PHT therapy. Of all the 12 patients, clinically examined five
patients showed grade II gingival enlargement and remaining
seven patients showed grade III gingival enlargement. None
of these cases had grade I enlargement (Fig. 3).
On histopathological examination, the section with these
second degree of gingival enlargement showed the following
changes in the submucosal layer. One case showed less
degree of fibroblastic proliferation and remaining four cases
of second degree drug enlargement showed moderate degree
of fibroblastic activity (Fig. 4).
In third degree enlargement cases, except one case all
the remaining cases, showed dense degree of fibroblastic
activity. The remaining cases showed moderate degree of
fibroblastic activity. Three out of five in second degree
enlargement cases show minimum amount of macrophages
infiltration, one case showed moderate amount of
macrophages and remaining one case showed dense
infiltration of macrophages. Figure 5 showing basal
epithelium, fibrous stands, groups of inflammatory cells.
In cases showing third degree enlargement, two cases
showed minimum amount of infiltration of macrophages,
one case showed moderate amount of infiltration of
macrophages, remaining four cases showed the dense
infiltration of macrophages. Moving on to the infiltration
of lymphocytes, all the second degree enlargement cases
have minimum amount of infiltration. In the third degree
enlargement, three cases showed minimum amount of
infiltration of lymphocytes, three cases showed moderate
degree of lymphocytic infiltration and remaining one case
showed dense infiltration of lymphocytes (Fig. 6).
Collagenation and capillary proliferations in all the cases
followed the degree of enlargement. The grade of
inflammation seen in the slides made from the gingival
enlargement biopsy followed the grading of enlargement.
Fig. 1: Grade I: Phenytoin gingival hyperplasia
Fig. 2: Grade II: Phenytoin gingival hyperplasia
Fig. 3: Grade III: Phenytoin gingival hyperplasia
All the second degree enlargement showed signs of second
degree of inflammation and in cases of third degree
enlargement except one case all the other cases showed signs
of third degree of inflammation. The left over cases showed
second degree of inflammation (Fig. 7). Phenytoin gingival
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hyperplasia epithelium showing normal plaxiform pattern
and normal sub-epithelial connective tissue comprising
fibrous tissue in various discrepancies and accompanying
vascular structures. No evidence of inflammatory infiltrate
(magnification 100%).
Group II: This group consists of 12 epileptic patients
under DPH therapy. On clinical examination none of the cases
showed gingival enlargement. In this group, only five patients
showed minimum amount of fibroblastic activity and the
remaining seven cases showed nil or negligible amount of
fibroblastic activity. Like fibroblastic activity, the degree
of infiltration of macrophages is also followed, only five
cases showed minimum amount of infiltration and lymphocyte
infiltration is also seen only in three cases in minimum
degree. Collagenation and capillary proliferation followed
the degree of inflammation as only five cases showed the
signs of minimum degree of inflammation (see Table 2).
Plaque index means are as follows:
• Test group: 1.17356
• Control group: 0.7427833
Though the test group showed slight difference in plaque
index, it is not of much significance. Gingival index means
are as follows:
• Test group: 1.17356
• Control group: 0.7427833
There is no significance difference in gingival index
according to means.
Fig. 4: Phenytoin gingival hyperplasia—lining epithelium—shows
some degree of acanthosis with inflammatory cells beneath
Fig. 5: Basal epithelium, fibrous stands, groups of inflammatory cells
and showing edema in deeper plane with occasional macrophages
Fig. 6: Phenytoin gingival hyperplasia—epithelium with marked
plaxiformacanthosis showing inflammatory cells infiltrate, thickened
fibrous bands showing some degree of edema (×100)
Fig. 7: Phenytoin gingival hyperplasia epithelium showing normal
plaxiform pattern and normal subepithelial connective tissue
comprising fibrous tissue in various discrepences and accompanying
vascular structures. No evidence of inflammatory infiltrate (×100)
Table 2: Comprehensive histopathologic changes in the gingival tissues of patients
Fibroblast Macrophage Lymphocytes
Test Control Test Control Test Control
Means 2.3333 0.4166 2.0833 0.4166 0.9166 0.25
SD 0.6513 0.51493 0.90003 0.5149 0.5624 0.452
SE 0.1486472 0.2993927 0.20832
T test 12.87 5.5667 3.19988
p-value <0.001 <0.001 <0.01
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DISCUSSION
The introduction of PHT as an epileptic drug in human
beings in 1938 marked the beginning of a new stage in the
history of epileptic patients in particular grand mal epileptic
patients and decreased significantly not only the epileptic
attacks but also improving the quality of life. PHT, however,
also produces several side effects, including hypertrichosis,
hirsutism, vestibulocerebellar syndrome, megaloblastic
anemia and gingival overgrowth. The first reports of PHT-
induced gingival enlargement was made by Kimbal OP in
1939 and subsequent studies further confirmed this finding.
Despite the large number of research studies on this subject,
the etiology of PHT-induced gingival overgrowth and
associated factors that contribute to its development has not
yet been properly established. For each potentially associated
factor, like PHT concentration in blood, plaque accumulation,
inflammation, genetically determined, etc. conflicting results
have been reported. A comprehensive study of the various
factors, covering a sufficiently large sample to reach
conclusions with a high degree of statistical significance,
might help to clarify this issue.
 The present study was conducted to investigate whether
there is any relationship between the degree of enlargement
and their histopathologic sections and quantify the different
varieties of cells and to see whether there is any relationship
between them, degree of hyperplasia and inflammation. As
I see in my study that increase in the degree of gingival
hyperplasia coincides with the degree of inflammation. This
is in agreement with the Kimbal and Horan, Glickman I
and Lewitus15 Store and Leyarelli, Staple PH and Reed,
Hall WB,16 Nuk LK and Copper SH,17 Tigaran S18 and
Philstrom, Hardwick, Band Park SS.19 They all observed
significant relationship between the gingival hyperplasia and
the inflammation. In the phenytoin enlargement smears,
there is increase in number of cells particularly fibroblasts,
macrophages and lymphocytes than the control group.
There is an increase in collagenation, capillary
proliferation is also seen in the phenytoin enlargement areas.
Para or hyper keratosis and epithelial pearls also seen some
times in the phenytoin enlargement cases.20,21
Glickman I and Lewitus, Ohyumi M and Sooriya Murthy
N, Gowe DB and Elcy BM stating that phenytoin induces
changes in connective tissue followed by epithelium. It is
observed in the present study that there is comparative
increase of fibroblast along with macrophages. There is no
significant difference between two groups in plaque index
and gingival index between test and control groups. It is
observed in the present study that there is a significant
difference between the smears of phenytoin enlargement
and control group.22,23
SUMMARY AND CONCLUSION
Based on the unprecedented success in preventing the
attacks of epilepsy, it appears that the clinical use of PHT
may increase significantly in the near future. Consequently,
cases of PHT-induced gingival hyperplasia could become a
far more common problem confronting the dental profession.
As a result, the services of dentists, dental hygienists and
dental specialists, particularly periodontists, would be sought
for prevention control and treatment of this type of gingival
hyperplasia. There is significance difference in gingival
index according to means.
Many periodontists presently treat patients who exhibit
gingival hyperplasia induced by PHT therapy. It is observed
that less than 1% of the population is on chronic PHT therapy
and that of these, approximately 50% will exhibit atleast
minimal gingival hyperplasia. As the patients on PHT is on
rise, this figure may increase. Although these observations
do not exclude other phagocytic cell types, e.g. neutrophils
or fibroblasts, they strongly support the hypothesis that at
some point during the course of PHT-induced connective
tissue proliferation, there are significantly larger numbers
of macrophages present.
Thus, in some ways, PHT appears to mimic endogenous
signals for wound repair or remodeling. At the usual
therapeutic dose level, these PHT effects must be at
subthreshold. However, in inflamed gingiva, a tissue
normally expressing a high rate of remodeling, the effects
of PHT could act synergistically with endogenous signals
resulting in excessive repair or overgrowth. The growth
promoting effects of PHT are not limited to the gingiva, but
are found in other types of connective tissue. This fact is
borne out by the results of this study. PHT must therefore
be considered to have rather broad effect on connective
tissues, the connective tissue of the gingiva being one of
the most susceptible.
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